Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 01 2020 - 10:44AM
Business Wire
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty
pharmaceutical company focused on identifying, developing and
commercializing products for the critical care market, today
announced that management is scheduled to present and conduct
one-on-one meetings at the H.C. Wainwright 22nd Annual Global
Investment Conference to be held virtually on September 14th-16th.
Anthony DiTonno, Chief Executive Officer, is scheduled to present
on Wednesday, September 16th at 10:30 a.m. Eastern Time.
A webcast of the presentation will be available on the “Events
and Presentations” page of the Investors section of the Company's
website. A replay of the webcast will be available for 30 days
following the event. For more information, please visit
investors.tenaxthera.com.
About Tenax Therapeutics
Tenax Therapeutics, Inc., is a specialty pharmaceutical company
focused on identifying, developing, and commercializing products
that address cardiovascular and pulmonary diseases with high unmet
medical need. The Company has a world-class scientific advisory
team including recognized global experts in pulmonary hypertension.
The Company owns North American rights to develop and commercialize
levosimendan and has recently released topline data regarding their
Phase 2 clinical trial for the use of levosimendan in the treatment
of Pulmonary Hypertension associated with Heart Failure and
preserved Ejection Fraction (PH-HFpEF). For more information, visit
www.tenaxthera.com.
About Levosimendan
Levosimendan is a calcium sensitizer that works through a unique
triple mechanism of action. It initially was developed for
intravenous use in hospitalized patients with acutely decompensated
heart failure. It was discovered and developed by Orion Pharma,
Orion Corporation of Espoo Finland, and is currently approved in
over 60 countries for this indication and not available in the
United States. Tenax Therapeutics acquired North American rights to
develop and commercialize levosimendan from Phyxius Pharma,
Inc.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by
the Company that involve risks and uncertainties and reflect the
Company’s judgment as of the date of this release. The
forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to matters beyond the
Company’s control that could lead to delays in the clinical study,
new product introductions and customer acceptance of these new
products; matters beyond the Company’s control that could impact
the Company’s continued compliance with Nasdaq listing
requirements; the impact of management changes on the Company’s
business and unanticipated charges, costs and expenditures not
currently contemplated that may occur as a result of management
changes; and other risks and uncertainties as described in the
Company’s filings with the Securities and Exchange Commission,
including in its annual report on Form 10-K filed on March 30,
2020, and its quarterly report on Form 10-Q filed on August 14,
2020, as well as its other filings with the SEC. The Company
disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. Statements in this
press release regarding management’s future expectations, beliefs,
goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200901005031/en/
Investor Contact: Westwicke, an ICR company Stephanie
Carrington, 646-277-1282 Stephanie.carrington@westwicke.com
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Apr 2023 to Apr 2024